Shares of Pharvaris (NASDAQ:PHVS - Get Free Report) saw unusually-high trading volume on Thursday . Approximately 52,867 shares changed hands during trading, an increase of 12% from the previous session's volume of 47,296 shares.The stock last traded at $17.44 and had previously closed at $17.17.
Wall Street Analyst Weigh In
Separately, JMP Securities upped their target price on Pharvaris from $46.00 to $55.00 and gave the stock a "market outperform" rating in a research report on Friday, January 31st.
Check Out Our Latest Analysis on Pharvaris
Pharvaris Stock Performance
The company's 50 day moving average is $18.49 and its 200 day moving average is $19.34. The stock has a market capitalization of $933.90 million, a price-to-earnings ratio of -6.38 and a beta of -3.08.
Hedge Funds Weigh In On Pharvaris
Large investors have recently added to or reduced their stakes in the company. Public Employees Retirement System of Ohio bought a new stake in shares of Pharvaris during the third quarter valued at approximately $57,000. Barclays PLC acquired a new position in shares of Pharvaris in the 3rd quarter valued at $106,000. Geode Capital Management LLC lifted its holdings in shares of Pharvaris by 18.4% during the 3rd quarter. Geode Capital Management LLC now owns 36,977 shares of the company's stock worth $685,000 after acquiring an additional 5,753 shares during the period. HighVista Strategies LLC boosted its position in shares of Pharvaris by 35.9% during the 3rd quarter. HighVista Strategies LLC now owns 22,768 shares of the company's stock valued at $422,000 after acquiring an additional 6,018 shares in the last quarter. Finally, Palumbo Wealth Management LLC bought a new stake in Pharvaris in the fourth quarter valued at about $196,000.
About Pharvaris
(
Get Free Report)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
See Also
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
